David Hallal Sells 1,171 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) Director David Hallal sold 1,171 shares of the stock in a transaction dated Thursday, June 9th. The shares were sold at an average price of $19.51, for a total value of $22,846.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
ITOS stock traded down $1.03 during mid-day trading on Friday, reaching $17.75. The company had a trading volume of 333,807 shares, compared to its average volume of 509,999. The stock has a 50 day simple moving average of $24.95 and a two-hundred day simple moving average of $33.03. The company has a market capitalization of $630.85 million, a price-to-earnings ratio of 2.27 and a beta of 2.03. iTeos Therapeutics, Inc. has a 52 week low of $16.21 and a 52 week high of $52.43.
iTeos Therapeutics (NASDAQ:ITOS – Get Rating) last issued its earnings results on Thursday, May 12th. The company reported $1.82 EPS for the quarter, topping the consensus estimate of $0.80 by $1.02. The business had revenue of $152.52 million for the quarter, compared to the consensus estimate of $63.30 million. As a group, equities analysts expect that iTeos Therapeutics, Inc. will post 4.38 EPS for the current fiscal year.
Separately, Piper Sandler dropped their price target on iTeos Therapeutics from $42.00 to $34.00 in a research report on Wednesday, May 11th.
A number of large investors have recently added to or reduced their stakes in ITOS. BlackRock Inc. lifted its holdings in iTeos Therapeutics by 106.5% during the 1st quarter. BlackRock Inc. now owns 3,331,313 shares of the company’s stock worth $107,203,000 after purchasing an additional 1,718,085 shares during the last quarter. State Street Corp lifted its holdings in iTeos Therapeutics by 124.3% during the 1st quarter. State Street Corp now owns 1,711,891 shares of the company’s stock worth $55,089,000 after purchasing an additional 948,540 shares during the last quarter. Tang Capital Management LLC raised its holdings in iTeos Therapeutics by 310.2% in the 3rd quarter. Tang Capital Management LLC now owns 900,000 shares of the company’s stock valued at $24,300,000 after acquiring an additional 680,604 shares in the last quarter. RTW Investments LP raised its holdings in iTeos Therapeutics by 37.1% in the 3rd quarter. RTW Investments LP now owns 2,353,015 shares of the company’s stock valued at $63,531,000 after acquiring an additional 636,430 shares in the last quarter. Finally, Pacer Advisors Inc. acquired a new position in iTeos Therapeutics in the 1st quarter valued at $14,271,000. 94.71% of the stock is owned by institutional investors and hedge funds.
iTeos Therapeutics Company Profile (Get Rating)
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company’s product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
Receive News & Ratings for iTeos Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for iTeos Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.